Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): a Southwest Oncology Group Phase II study.
about
Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618.Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420.The role of chemotherapy in the management of patients with head and neck cancer.Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancerPhase II study of TAS-106 in patients with platinum-failure recurrent or metastatic head and neck cancer and nasopharyngeal cancer.Recurrent head and neck cancer: current treatment and future prospects.Optimal treatment for recurrent/metastatic head and neck cancer.Treatment of head and neck cancer in the elderly.Triweekly reduced-dose docetaxel combined with cisplatin in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase II study.AHNS Series: Do you know your guidelines? Principles of treatment for locally advanced or unresectable head and neck squamous cell carcinoma.Chemoradiotherapy with weekly low-dose docetaxel and cisplatin concurrent with radiation for patients with locally advanced nasopharyngeal carcinoma, followed by adjuvant chemotherapy for selected patients.Incidence and predictors of febrile neutropenia during chemotherapy in patients with head and neck cancer.Pretreatment monocyte counts and neutrophil counts predict the risk for febrile neutropenia in patients undergoing TPF chemotherapy for head and neck squamous cell carcinoma.
P2860
Q33941497-05533970-B1EB-4BA9-B23B-DAFE38F8E20BQ33990908-3A65497C-6121-4483-8659-AD88F3034DD4Q35882999-E010F32E-083E-4233-84DA-4A894CECD76CQ36301182-8515E59A-CC68-474F-AF7B-E768595DACF3Q36977432-B5AC023D-F5A5-4544-BBB0-DA760236BF97Q37118936-20DAB413-788C-4B7B-89E9-CA81E8FE0AB3Q37799934-4AC54EF9-F908-4929-BEE4-8E84B37689F6Q38958367-F5E141D2-72E4-4A77-90AF-6E08DB27E5C9Q43906898-DBDB25D7-88FB-4103-B504-559F3C5D65B4Q48240243-374024E4-5CC0-4E51-9576-94A1F62E6EFBQ49148069-2380AAAB-428E-40D6-880C-0464D1FD2CA6Q50848240-5E4DDD1F-9FE0-4545-B18A-66AC91784717Q55322325-F3436CD9-465E-44F6-AF05-6F6C208AAB98
P2860
Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): a Southwest Oncology Group Phase II study.
description
2007 nî lūn-bûn
@nan
2007 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
name
Evaluation of the combination ...... Oncology Group Phase II study.
@ast
Evaluation of the combination ...... Oncology Group Phase II study.
@en
Evaluation of the combination ...... carcinoma of the head and neck
@nl
type
label
Evaluation of the combination ...... Oncology Group Phase II study.
@ast
Evaluation of the combination ...... Oncology Group Phase II study.
@en
Evaluation of the combination ...... carcinoma of the head and neck
@nl
prefLabel
Evaluation of the combination ...... Oncology Group Phase II study.
@ast
Evaluation of the combination ...... Oncology Group Phase II study.
@en
Evaluation of the combination ...... carcinoma of the head and neck
@nl
P2093
P2860
P1433
P1476
Evaluation of the combination ...... Oncology Group Phase II study.
@en
P2093
Craig R Nichols
David E Schuller
Howard Ozer
J Philip Kuebler
James Moon
James N Atkins
John F Ensley
Stephen K Williamson
Wolfram E Samlowski
P2860
P304
P356
10.1080/07357900701209061
P577
2007-04-01T00:00:00Z